Analysis of drug resistance to six kinds of nucleoside analogues in 1507 patients with viral hepatitis B

Objective To analyze the drug resistance of hepatitis B virus (HBV) in patients under antiviral therapy with nucleoside analogues. Methods The patients were from the overall country of China and the specimens were tested in Guangzhou Kingmed Center for Clinical Laboratory during Jan 1, 2016 and Mar 25, 2016. The nucleoside analogues resistance genes were detected in 1507 patients with hepatitis B, and the drug resistance of six common nucleoside analogues were collected and classified. Results The drug-resistance of lamivudine (LAM), telbivudine (LDT) and emtrichomes (FTC) were serious, and the drug resistance rates were 35.24 %. The drug-resistance of adefovir (ADV) and entecavir (ETV) were also high, which were 14.93 % (225/1507) and 7.70 %(116/1507), respectively. No strain resistant to tenofovir (TDF) were found in the 1507 cases. Conclusions Low drug resistance barrier drugs including lamivudine, telbivudine and emtrichomes have severe resistance. Nucleoside analogues resistance gene monitoring is effective in the formulation of drug use protocols. It has an important clinical significance to improve the prognosis of patients and track investigation of drug resistance situation to reduce or delay the production of drug resistant strains. Key words: Hepatitis B virus; Drug resistance; Chronic hepatitis B; Rational drug use